The University of Copenhagen is excited to announce Longevity Investors as Tier 4 Sponsor of the 12th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in the biopharmaceutical industry that will transpire on August 25 - August 29, 2025 on-site at the Ceremonial Hall, University of Copenhagen, and online.
Longevity Investors brings together a carefully selected audience of the most prominent investors in the longevity space. We build premier, investor-focused platforms designed to foster year-round engagement between world-leading longevity scientists, visionary investors, and mission-driven entrepreneurs - all with the goal of accelerating progress in the longevity sector.
Our mission is to advance understanding, collaboration and investment in longevity science, and bridge the gap between cutting-edge longevity science and the capital needed to scale it.
We aim to position longevity as a smart, long-term investment class and help shape it into one of the most impactful industries of the 21st century.
Our exclusive events, leading with our flagship event - the Longevity Investors Conference in Gstaad, Switzerland - offer an immersive experience that combines thought-provoking discussions, expert-led education, and curated networking opportunities in a luxurious, carefully selected setting. With an emphasis on fostering impactful relationships, we provide a space where the world’s top longevity KOLs, institutional and private investors, family offices, and funds can gain unique insights into longevity trends alongside an elite network of like-minded individuals.
Longevity Investors is evolving into a year-round platform focused on longevity investment and investors. Beyond the conference, we host events like the Longevity Investors Lunch during the World Economic Forum in Davos — next year will already be our fifth edition. We also collaborate globally, for example partnering with the XPRIZE Foundation for an Investors Summit in New York. We launched Longevity Investors News to track key investment trends and stories, and we’re working on more partnerships to bring our investment-focused format to other regions, including in Asia and the Middle East, where interest in health span and longevity is growing rapidly.
Tobias Reichmuth, a Co-Founder of Longevity Investors, emphasized the scale of the opportunity. “The longevity sector is rapidly emerging as one of the most compelling investment themes of our time, with projections valuing it at over $600 billion by 2026,” he said. “With growing momentum and breakthroughs happening at pace, now is the perfect moment to raise awareness and equip investors with the knowledge to engage in this transformative space.”
“At Longevity Investors, we believe that the convergence of cutting-edge science and visionary capital is the key to transforming how we age. Our mission is to accelerate this transformation by connecting the brightest minds in longevity with the investors who are ready to shape the future of health.”
— Lucia Kupcova, CEO, Longevity Investors
--------
ARDD has grown to become the largest and most important conference in longevity biotechnology. Each year, ARDD brings together a unique mix of academic luminaries, biotech innovators, investors, top pharmaceutical executives, physicians, and related health care professionals to discuss the latest advancements in aging research and the event provides unique opportunities to connect with brilliant minds, fostering collaboration and showcasing groundbreaking research in the field.
“We are extremely honored to host Professors Meldal and Levitt at ARDD2025. Their Nobel prize winning discoveries have been instrumental for drug development and molecular design in part through modelling of proteins and molecules, and in part through the ability to easily create new molecules. It is therefore a great pleasure that they are joining our conference.” said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.
“We are really excited for ARDD2025, especially with Nobel Laureates Morten Meldal and Michael Levitt joining us. Their groundbreaking contributions have had a lasting impact on drug discovery, and having them at the conference is sure to make it an unforgettable experience.” said Daniela Bakula, Ph.D., University of Copenhagen.
“For 12 years, the Aging Research and Drug Discovery (ARDD) forum grew in size and in quality. It became the world’s main platform for academia-pharma-startup-investor partnership and dialogue. In 2025, the conference will feature the Nobel laureates, pharmaceutical industry executives and healthcare delivery leaders. ARDD is a unique platform for advancing longevity biotechnology around the world.” said Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine.
“At ARDD we strive to highlight the cutting-edge research and clinical applications in a new discipline of healthy longevity medicine. Having Nobel laureates join and speak at the ARDD conference underscores the critical importance of grounding longevity science and medicine in evidence-based, scientifically rigorous approaches.” said Prof.Dr.Evelyne Bischof, the organizer of the Longevity Medicine Days.
Aging research has become a great platform for advancing drug discovery with blockbuster potential, with pharmaceutical leaders like Novartis, Biogen, and Eli Lilly actively supporting this transformative field. ARDD has established itself as the go-to venue where scientists and pharma companies collaborate, share insights, and launch aging-focused research initiatives. In 2024, industry leaders such as Eli Lilly, Novartis, Regeneron, Biogen, and Lundbeck presented their latest research at ARDD, highlighting the meeting's pivotal role in advancing healthspan and longevity science. Be part of ARDD 2025 and contribute to shaping the future of medicine.
For further information, images or interviews, please contact:
ardd@pharma.ai
About Aging Research for Drug Discovery Conference
At ARDD, leaders in the aging, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the meeting will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. Notably, this year we will have a special day called Longevity Medicine Day, specifically for physicians where the leading-edge knowledge of clinical interventions for healthy longevity will be described. ARRD intends to bridge clinical, academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. Our quest to extend the healthy lifespan of everyone on the planet.